Uncertain Future For Orphazyme After Arimoclomol Snub In Europe
European Medicines Agency Likely To Advise Rejection Of Arimoclomol For Niemann-Picks Type C
The EMA's medicines evaluation committee has told Orphazyme it is unlikely to recommend approval of the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.
